Ustekinumab vs. Vedolizumab vs. Tofacitinib: The Head-to-Head TNFi-Experienced UC Data Payers and HEOR Teams Need

 Key Takeaways

• In an independent peer-reviewed study directly comparing 2,141 TNFi-experienced UC patients, ustekinumab outperformed both vedolizumab and tofacitinib on composite efficacy, colectomy risk, and two-year therapy durability. 
• Tofacitinib showed the lowest IV steroid use among the three agents but carried the highest colectomy risk — nearly 2.6 times greater than ustekinumab — and the lowest durability, with 19.5% of patients requiring a therapy change within two years. 
• For market access, HEOR, and commercial teams operating in the second-line UC space, this study provides the kind of real-world evidence that formulary decisions and value dossiers require and that single-site datasets cannot generate. 

In a crowded second-line ulcerative colitis (UC) market, the question isn’t whether a therapy works in a controlled trial. It’s what happens when it’s deployed in real-world clinical practice, in patients who have already failed a TNF inhibitor (TNFi), across a population diverse enough to matter to payers and health technology assessment bodies. 

That evidence has been hard to come by. Head-to-head comparative data in TNFi-experienced UC patients is limited, and the absence of it creates a real problem: commercial, market access, and Health Economics and Outcomes Research (HEOR) teams are asked to build formulary arguments, payer submissions, and value dossiers without the direct comparative evidence those audiences are looking for. 

An independent study by Kochhar et al. (Aliment Pharmacol Ther. 2023 Aug;58(3):297-308) conducted utilizing real-world data (RWD) from the TriNetX LIVE™ platform fills a meaningful portion of that gap. 

What the Study Examined

Researchers used de-identified electronic health records (EHRs) from more than 85 million patients to compare three second-line therapy options in adults with UC who had prior TNFi exposure: ustekinumab, vedolizumab, and tofacitinib. 

The study cohort included 2,141 patients who initiated second-line therapy after November 2019. Propensity score matching balanced cohorts across demographics, disease extent, prior TNFi exposure type, comorbidities, and baseline laboratory values. Outcomes tracked included a composite of intravenous (IV) steroid-requiring hospitalization or colectomy, therapy durability over two years, and safety events in year one. 

The scale here is worth noting. No single-site dataset could assemble a TNFi-experienced UC population of this size with the clinical depth needed for rigorous comparative analysis. This is the kind of study that only a connected RWD network like TriNetX LIVE™ makes possible. 

The Findings, Side by Side

For teams that need to communicate this evidence quickly and clearly across commercial, market access, and HEOR functions, the data organizes itself into a straightforward comparison. 

Outcomes from a retrospective cohort study of 2,141 TNFi-experienced UC patients within the TriNetX Network. Source: TriNetX CSO Perspectives: Research Impact Report. 

A few findings deserve emphasis for teams building the commercial evidence story. 

• Ustekinumab’s durability advantage is substantial. At two years, only 7.1% of patients on ustekinumab required a therapy change, compared with 12.8% on vedolizumab and 19.5% on tofacitinib. The adjusted odds ratio for switching from tofacitinib versus ustekinumab was 2.38. In market access terms, durability data of this quality — drawn from real-world practice, not a trial — is exactly what payers and formulary committees are looking for. 
• The tofacitinib picture is nuanced and commercially significant. Tofacitinib showed the lowest IV steroid use in the vedolizumab comparison, which may register as a short-term steroid-sparing advantage. But that finding is substantially offset by a colectomy risk nearly 2.6 times higher than ustekinumab. For HEOR and market access teams modeling long-term cost and burden, colectomy risk is not a peripheral metric; it is one of the highest-cost outcomes in UC management. 
• Vedolizumab showed intermediate performance across outcomes. Compared to ustekinumab, vedolizumab carried higher risk on the composite efficacy outcome, driven by IV steroid use, and worse durability. It outperformed tofacitinib on colectomy risk. 

On the safety side, no significant differences were observed across all three agents in major adverse cardiovascular events, malignancy, venous thromboembolism, or opportunistic infections within the first year. 

What This Means for Commercial and Market Access Strategy

Second-line UC is a high-stakes positioning environment. Multiple mechanisms compete for the same refractory population, and the clinical evidence landscape is fragmented. Studies like this one matter precisely because they generate the comparative sequencing data that moves formulary decisions. 

Payers evaluating second-line UC therapies want to see real-world outcomes in populations that look like their members: patients who have failed TNFi therapy, presenting across diverse care settings, with the follow-up data to assess durability, not just short-term response. 

The study delivers on all three dimensions: a large, clinically representative TNFi-experienced cohort; head-to-head comparison across the three most relevant second-line agents; and two-year durability data that reflects what happens in practice, not under trial conditions. 

For value dossier development, payer engagement, and HEOR submissions, these findings provide a foundation that positions ustekinumab on the outcomes that matter most in real-world UC management. 

About Jeffrey Brown, PhD 

With more than 25 years of experience in research and consulting, Jeff is an internationally recognized expert in the use of RWD to support the evidentiary needs of regulatory agencies and medical product sponsors and an expert in the assessment of data quality of RWD resources.